AGTC - Applied Genetic Technologies Corporation
| Previous Close | 3.8800 |
| Open | 3.8500 |
| Bid | 2.1900 x 1000 |
| Ask | 6.0000 x 1100 |
| Day's Range | 3.8500 - 3.9900 |
| 52 Week Range | 2.2600 - 7.5000 |
| Volume | 52,362 |
| Avg. Volume | 45,440 |
| Market Cap | 70.505M |
| Beta (3Y Monthly) | 3.76 |
| PE Ratio (TTM) | 41.28 |
| EPS (TTM) | 0.0940 |
| Earnings Date | Feb 6, 2018 - Feb 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.60 |
- Simply Wall St.•2 days ago
Is Applied Genetic Technologies Corporation (NASDAQ:AGTC) Overpaying Its CEO?
Sue Washer has been the CEO of Applied Genetic Technologies Corporation (NASDAQ:AGTC) since 2002. This analysis aims...
- Zacks•8 days ago
Horizon Therapeutics Files BLA to FDA for Eye Disease Drug
Horizon Therapeutics (HZNP) files a BLA for teprotumumab to the FDA for the treatment of active thyroid eye disease.
- Zacks•9 days ago
Mirati Inks Deal with Novartis to Evaluate Tumor Candidate
Mirati (MRTX) inks a clinical collaboration with Novartis to evaluate the combination of the former's MRTX849 and the latter's SHP2 inhibitor, TNO155, in patients with advanced solid tumors.
- Zacks•9 days ago
Kadmon Initiates Dosing in Study for Systemic Sclerosis Drug
Kadmon (KDMN) doses first patient in a phase II study of KD025 for the treatment of diffuse cutaneous systemic sclerosis (SSc).
- Zacks•11 days ago
ObsEva Ends Recruitment in Second Uterine Fibroids Study
ObsEva (OBSV) completes patient recruitment in the second pivotal phase III study evaluating linzagolix for the treatment of heavy menstrual bleeding (HMB) associated with uterine fibroids.
- Zacks•14 days ago
Catalyst Pharma Focuses on Firdapse Launch & Label Expansion
Catalyst Pharmaceuticals (CPRX) intends to launch Firdapse and expand the label of the same.
- Zacks•21 days ago
Novavax (NVAX) Seeks Accelerated Approval Pathway for NanoFlu
Novavax (NVAX) seeks to use accelerated approval pathway for its influenza vaccine candidate, NanoFlu, in the United States.
- Zacks•24 days ago
Alnylam Presents New Data for RNAi Therapeutic Onpattro
Alnylam (ALNY) announces new results from the Global Open-Label Extension study of Onpattro at the 2019 Peripheral Nerve Society (PNS) Annual Meeting.
- GlobeNewswire•24 days ago
AGTC Announces New Leadership Appointments
Global Clinical and Medical Affairs Veteran, Theresa G.H. Heah, M.D., M.B.A., to Join AGTC as Chief Medical Officer Brian Krex Named General Counsel GAINESVILLE, Fla. and.
- Zacks•25 days ago
Epizyme Announces Positive Interim Data on Lead Candidate
Epizyme (EPZM) announces positive interim data from an ongoing phase II study of its lead candidate, tazemetostat.
- Zacks•25 days ago
AMAG's Vyleesi Gets FDA NOD for Women with Low Sexual Desire
AMAG Pharmaceuticals (AMAG) announces that the FDA has approved Vyleesi to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women.
- Zacks•29 days ago
Ultragenyx & Arcturus Therapeutics Expand Existing Agreement
Ultragenyx (RARE) and Arcturus Therapeutics expand their existing collaboration to discover and develop mRNA, DNA and siRNA therapeutics for up to 12 rare disease targets.
- GlobeNewswire•last month
AGTC to Present at BMO Capital Markets 2019 Prescriptions for Success Healthcare Conference on June 25, 2019
GAINESVILLE, Fla., and CAMBRIDGE, Mass., June 18, 2019 -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of.
- Zacks•last month
Alexion's (ALXN) PNH Drug Ultomiris Shows Long-Term Efficacy
Alexion (ALXN) reports positive data on Ultomiris in adult patients with paroxysmal nocturnal hemoglobinuria.
- Zacks•last month
Dr. Reddy's Inks Deal to Sell Neurology Branded Products
Dr. Reddy's (RDY) announced that it has entered a definitive asset purchase agreement with Upsher-Smith Laboratories, LLC to sell its neurology branded products.
- Zacks•last month
Catalyst Pharma Files Lawsuit Against FDA Approval of Ruzurgi
Catalyst Pharma (CPRX) files lawsuit against FDA's approval of Jacobus Pharmaceutical Co's drug, Ruzurgi, for the treatment of LEMS in pediatric patients.
- Zacks•last month
Alkermes Initiates Monothearpy Expansion Phase of ALKS 4230
Alkermes (ALKS) initiates monotherapy expansion phase of ALKS 4230 to treat patients with renal cell carcinoma or melanoma.
- Zacks•last month
Is Applied Genetic Technologies (AGTC) Stock Outpacing Its Medical Peers This Year?
Is (AGTC) Outperforming Other Medical Stocks This Year?
- Zacks•last month
Novavax' Shares Drop as FDA Advises Another Study for Resvax
FDA recommends Novavax (NVAX) to conduct additional phase III study for its respiratory syncytial virus (RSV) vaccine candidate for infants, ResVax.
- Zacks•last month
bluebird's Zynteglo Gets EU Conditional Marketing Approval
bluebird bio (BLUE) announces that the EC has granted conditional marketing authorization to Zynteglo, its first gene therapy, for patients aged 12 years or older with TDT, who do not have a specific genotype.
- Zacks•2 months ago
Alnylam Initiates Phase I Study on Hypertension Candidate
Alnylam (ALNY) initiates phase I study on ALN-AGT, an investigational RNAi therapeutic targeting angiotensinogen for the treatment of hypertension in high unmet need populations.
- Zacks•2 months ago
Mallinckrodt to Spin Off Specialty Generics Unit, Shares Down
Mallinckrodt (MNK) will spin-off its Specialty Generics business to its shareholders.
- Zacks•2 months ago
Epizyme (EPZM) Shares Surge More Than 100% YTD: Here's Why?
Epizyme's (EPZM) share price soars more than 100% year to date. The company is progressing well with its pipeline candidate, Tazmetostat.
- Zacks•2 months ago
Dynavax (DVAX) to Cut Jobs and Focus on Vaccine Business
Dynavax (DVAX) announces restructuring measures to focus on vaccine business. The CEO of the company will retire on Aug 1, 2019.
- Zacks•2 months ago
Agenus' (AGEN) Pipeline Progression on Track Amid Competition
Agenus (AGEN) is developing its pipeline candidates and has an array of collaboration contracts to its credit that bodes well for growth.
